lunes, 20 de noviembre de 2023

Lebrikizumab Gets the Nod for Treating Moderate-to-Severe Atopic Dermatitis in Europe Heidi Splete

https://www.medscape.com/s/viewarticle/998647?src=

No hay comentarios:

Publicar un comentario